Therefore, there is a need for the further screening of multi-functional drugs able to target AD symptoms including decreased acetylcholine levels, protein misfolding and associated Aβ aggregation, hyperphosphorylation of the tau protein and oxidative stress. This evidence concerns the gene MAPT and Alzheimer disease.